An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if ganetespib (STA-9090) is effective in the
treatment of patients with HER2+ or triple negative breast cancer who have not received prior
systemic treatment in the metastatic setting.